The U.S. Supreme Court declined to hear multiple biopharma challenges to the Inflation Reduction Act’s Medicare drug price negotiation program, dealing another blow to the brand-drug industry’s legal campaign. The petitions covered AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Novo Nordisk, according to court order summaries. The decision follows losses in lower courts and comes as companies argue the negotiated-price framework infringes on investment-backed patent rights and reduces market pricing. The Supreme Court’s refusal to take up the cases effectively keeps the IRA negotiation structure intact. For manufacturers with meaningful Medicare Part D exposure, the ruling narrows the pathway for litigation-based relief and increases pressure to plan commercial strategies around IRA-linked pricing trajectories.